Nanobiotix(NBTX)
PARIS, FranceBiotechnology
Focus: Nanobiotix is a publicly-traded French biotechnology company specializing in nanoparticle-based therapeutics for oncology, with a clinical-stage pipeline anchored by NBTXR3 across multiple solid tumors.
Profile data last refreshed 3h ago · AI intelligence enriched 2w ago
Funding Stage
PUBLIC
Open Jobs
0
About Nanobiotix
AI assessmentNot HiringNo open roles listed right now. Follow Nanobiotix to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
1/9 — Limited
Company HealthSolid
Pipeline
Early-stage
7 total
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
NBTXR3 activated by IMRT
Head and Neck CancerClinical Trials (1)
NCT01946867NBTXR3 and Radiation Therapy in Treating Patients With Locally Advanced SCC of the Oral Cavity or Oropharynx
N/AHelp build intelligence for Nanobiotix
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.